Richmond Pharmacology are pleased to announce our participation in the American Heart Association’s Hypertension Scientific Sessions 2025, held in Baltimore from 4–7 September.
Representing Richmond at Hypertension 2025:
Dr Jörg Täubel, Chief Executive Officer
James Rickard, Chief Scientific Officer
Our team will be available to discuss Richmond’s expertise in:
Early-phase hypertension and cardiovascular research
First-in-human and dose-response studies
Ambulatory BP monitoring and novel endpoints
Regulatory strategy and global trial delivery
Targeted recruitment and patient-centric design
If you’re attending Hypertension 2025 and seeking a partner in hypertension clinical development, we welcome meeting requests at: info@richmondpharmacology.com
Richmond Pharmacology Appoints John Hotti as Chief Technology Officer
April 22, 2026
Richmond Pharmacology is pleased to announce the appointment of John Hotti as Chief Technology Officer (CTO), strengthening the company’s leadership in technology-enabled clinical research.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
